Efficacy of Infliximab in Intestinal Behçet’s Disease

• DOI: 10.1097/mib.0b013e31828f19c9
• Publication Date: 2013-05-23T18:42:20Z
• Authors: Jin Ha Lee; Jae Hee Cheon; Seong Woo Jeon; Byong Duk Ye; Suk-Kyun Yang; Young-Ho Kim; Kang-Moon Lee; Jong Pil Im; Joo Sung Kim; Chang Kyun Lee; Hyo Jong Kim; Eun Young Kim; Kyeong Ok Kim; Byung Ik Jang; Won Ho Kim
• Keywords: Concomitant

Although infliximab is widely accepted as a therapeutic option for inflammatory bowel disease, its efficacy the treatment of intestinal Behçet’s disease (BD) unknown. We investigated short-term and long-term response rates to in BD predictive factors sustained following treatment. This study was conducted using retrospective noncontrolled review medical records from 8 tertiary hospitals Korea. collected clinical, demographic, laboratory data patients with 28 who received at least 1 dose infliximab. Response 2, 4, 30, 54 weeks each patient were investigated. Adverse events also identified. The median duration follow-up after initial infusion 29.5 months. clinical 75%, 64.3%, 50%, 39.1%, respectively, remission 32.1%, 28.6%, 46.2%, respectively. After multivariate analysis, older age diagnosis (≥40 yr), female sex, longer (≥5 concomitant immunomodulator use, achievement week 4 found be response. There serious infection but no malignancies or deaths this study. Infliximab well-tolerated effective therapy moderate-to-severe BD. Moreover, we 5 associated response, which might assist optimal selection